Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Gastrointestinal 1CNS 1

Conditions

Neoplasms 1Leukemia, Myeloid, Acute 1Glioma 1Cholangiocarcinoma 1

Interventions

Specimen Handling 465Magnetic Resonance Spectroscopy 351pembrolizumab 297Biopsy 251Carboplatin 235Cisplatin 199Cyclophosphamide 191Paclitaxel 167Nivolumab 159Gemcitabine 154Radiotherapy 129Bevacizumab 128Dexamethasone 115fludarabine 103Pemetrexed 102Fluorouracil 96Radiation 94Doxorubicin 94atezolizumab 93Docetaxel 93durvalumab 92venetoclax 91Rituximab 89Oxaliplatin 89Leucovorin 82Capecitabine 79Prednisone 78Lenalidomide 72X-Rays 69Etoposide 69

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Cytochrome P-450 CYP3A × 30 days × Clear all
NCT07486713 2026-06-05

Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies

Rigel Pharmaceuticals

Phase 4 Recruiting
16 enrolled
CNSGastrointestinalOther hematologic neoplasm

Glioma, Neoplasms, Leukemia, Myeloid, Acute, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡